ESPR: Esperion Therapeutics, Inc. Company Profile & Statistics

Esperion Therapeutics, Inc. Profile

About

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

Info & Links

CEO

Sheldon L. Koenig

Headquarters

3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI 48108, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

294

Esperion Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization²

736.02M

Enterprise Value

817.65M

Enterprise Value/EBITDA(ttm)

12.90

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.67

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

63.25%

Operating Margin(ttm)

-3.66%

Profit Margin(ttm)

-19.22%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-74.11%

Return on Assets(ttm)

-3.93%

Income Statement

Revenue(ttm)

403.13M

Revenue Per Share(ttm)

1.57

Gross Profit(ttm)

273.91M

EBITDA(ttm)³

63.39M

Net Income Available to Common(ttm)

-22.68M

Diluted EPS(ttm)

-0.17

Share Statistics

Beta (5Y Monthly)

1.11

52-Week Change

69.94%

S&P 500 52-Week Change

13.77%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

256.81M

Dividend Yield

0.00%

Float⁴

252.44M

% Held by Insiders

1.70%

% Held by Institutions

47.39%

Balance Sheet

Total Cash(mrq)

167.85M

Total Cash Per Share(mrq)

0.65

Total Debt(mrq)

249.48M

Total Debt/Equity(mrq)

-82.62%

Current Ratio(mrq)

1.54%

Quick Ratio(mrq)

1.19%

Book Value Per Share(mrq)

-1.23

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.06

Free Cash Flow(ytd)

-13.09M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ESPR

Esperion Therapeutics, Inc.